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FIG. 9: NanogP8 Sequence 
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atgagtgtggatccagcttgtccccaaagcttgccctgctttgaagaatccgactgtaaa 
M S V D P A C P Q 8 L P C F E E 8 D C K 
gaatcttcacctatgcctgtgatttgtgggcctgaagaaaactatccatccttgcaaatg 
E S S P M P V I C G P E E N Y P S L Q M 
tcttctgctgagatgcctcacacagagactgtctctcctcttccttcctccatggatctg 
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Lane 3: lOObp ladder 
Lane 4: lOµM 5--aza--C 
Lane 5: 3µM 5-aza-C 
Lane 6: lµM 5-aza-C 
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Lane 7: Negative control 
Lane 8: Positive control lx 
Lane 9: Positive control 2x 
Lane 10: lOObp ladder 
Treatment with 10, 3 or 1 uM of 5azaC for 
21 days, 5 days coculture. 
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FIG. 11 
3 weeks of treatment (3uM BrdU or 5-azaC) and coculture for 7 days 
Lane 2: ladder 
Lane 3: Troponin I or GATA-4 low RNA of BrdU treatment 
Lane 4: Troponin I or GATA-4 high RNA of BrdU treatment 
Lane 5: Troponin I or GATA-4 low RNA of 5azaC treatment 
Lane 6: Troponin I or GATA-4 high RNA of 5azaC treatment 
Lane 7: ladder 
Lane 8: hANP or MLC-2v low RNA of BrdU treatment 
Lane 9: hANP or MLC-2v high RNA of BrdU treatment 
Lane 10: hANP or MLC-2v low RNA of 5azaC treatment 
Lane 11: hANP or MLC-2v high RNA of 5azaC treatment 
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GATA-4 and MLC-2v 
Lane 1: lOObp ladder 
Lane 2: 3uM combined treatment 3 weeks 
Lane 3: 1 uM combined treatment 3 weeks 
Lane 4: 3uM 5azaC 3 weeks 
Lane 5: 3uM BrdU 3 weeks 
Lane 6: 3uM Control (nt 12/27) 
Lane 7: 3uM combined treatment 3 weeks 
Lane 8: luM combined treatment 3 weeks 
Lane 9: 3uM 5azaC 3 weeks 
Lane 10: 3uM BrdU 3 weeks 
Lane 11: 3uM Control (nt 12/27) 
Lane 12: lOObp ladder 
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GATA-4 and MLC-2v 
Lane 1: DNA ladder 
Lane 2: lOuM 5azaC treatment 
Lane 3: 3uM 5azaC treatment 
Lane 4: luM 5azaC treatment 
Lane 5: 3uM 5azaC treatment 
Lane 6: 3uM BrdU treatment 
Lane 7: lOuM 5azaC treatment 
Lane 8: 3uM 5azaC treatment 
Lane 9: luM 5azaC treatment 
Lane 10: 3uM 5azaC treatment 
Lane 11: 3uM BrdU treatment 
Lane 12: DNA ladder 
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METHODS AND MATERIALS FOR 
INCREASING POTENCY OF CELLS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
FIG. 8 shows images ofMeSC-derived neurons and astro-
cytes. 
FIG. 9 shows sequence ofNanog encoding polynucleotide 
and corresponding polypeptide sequence. 
This application is a continuation of U.S. patent applica-
tion Ser. No. 11/258,401 filed Oct. 24, 2005, now issued as 
U.S. Pat. No. 8,192,988; and which claims priority to U.S. 
Provisional Application No. 60/621,901 filed Oct. 22, 2004 10 
and 60/650,438 filed Feb. 4, 2005, both of which are incor-
porated herein in their entirety 
FIGS. 10-13 shows gel images of gene expression in cells 
subjected to various treatments demonstrating an ability to 
increase potency of mesenchymal stem cells and differentia-
tion into cardiac cells. 
FIGS. 14-16 show photograph images of cells subjected to 
various treatments. 
FIG. 17 shows a schematic representation of the nanog 
sequence cloned inside a CMV mammalian promoter vector. 
BACKGROUND OF THE INVENTION 
The use of stem cells for the treatment of neurodegenera-
tive conditions offers the hope of curing diseases like Alzhe-
imer's and Parkinson's by means of transplantation [1]. How-
ever, major obstacles regarding cell procurement, directing 
cell fate and avoiding immune response hinder clinical devel-
opment [2-4] Research has focused on both adult and embry-
onic stem cells and attempted to balance limitations in regu-
lating their development and preventing immune response. 
Increased potency of stem cells can be achieved by epigenetic 
modifications through nucleotide derivatives [5] and their 
lineage can be directed by gene transfection [ 6, 7]. 
Patients currently suffering from neurodegenerative con-
ditions have limited treatment options. Conventional drug 
therapy helps delay or reduce the symptoms of disease but is 
unable to restore complete functionality of the brain or repair 
damaged tissue. Through stem cell-based therapies, scientists 
aim to transplant cells in order to regenerate damaged tissue 
and restore proper function. However, the best source of stem 
cells for transplantation remains an unresolved issue; with 
debate focusing around embryonic or adult derived stem 
cells. Embryonic stem cells can be readily differentiated to 
multiple neuronal fates but pose the risk of tumor formation 
or immune response; whereas adult stem cell technology is 
easily accessible, but provides limited capacity for transdif-
ferentiation. An optimal approach may be to increase cellular 
plasticity of adult stem cells for use in autologous transplan-
tation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the vector system for cloning nanog accord-
ing to the teachings in Example 1. 
FIG. 2 shows images of cells before and after transfection 
with nanog: A: shows mesenchymal stem cells pre-transfec-
tion; B: shows nanog-transfected mesenchymal stem cells 12 
days post-cells 12 days post-transfection; C: shows nanog-
transfected mesenchymal stem cells 4 weeks post-cells 4 
weeks post-transfection. 
FIG. 3 shows images of transfected mesenchymal stem 
cells 9 days (A and B) and 2 months (C and D) post transfec-
tion. 
FIG. 4 shows images a co-culture system in accord with 
one embodiment of the subject invention. 
FIG. 5 shows images of Co-culturing experiments which 
demonstrated that embryoid body-like clusters began differ-
entiation within 48 hours (A). Control cells with our empty 
vector treatments failed to show any signs of neural differen-
tiation (B). Embryoid-like bodies adhered to membrane and 
differentiation occurred as neural cells migrated radially out-
ward (C). 




In reviewing the detailed disclosure which follows, and the 
specification more generally, it should be borne in mind that 
all patents, patent applications, patent publications, technical 
publications, scientific publications, and other references ref-
20 erenced herein are hereby incorporated by reference in this 
application, in their entirety to the extent not inconsistent with 
the teachings herein. 
Reference to particular buffers, media, reagents, cells, cul-
ture conditions and the like, or to some subclass of same, is 
25 not intended to be limiting, but should be read to include all 
such related materials that one of ordinary skill in the art 
would recognize as being of interest or value in the particular 
context in which that discussion is presented. For example, it 
is often possible to substitute one buffer system or culture 
30 medium for another, such that a different but known way is 
used to achieve the same goals as those to which the use of a 
suggested method, material or composition is directed. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
35 unless defined herein, are intended to have the same meaning 
as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 
to one of ordinary skill in the art, unless stated otherwise. For 
purposes of more clearly facilitating an understanding the 
40 invention as disclosed and claimed herein, the following defi-
nitions are provided. 
The differentiation of stem cells along multiple lineages 
has been intensely studied given their great therapeutic poten-
tial. However, the mechanisms that underlie proliferation, 
45 self-renewal and differentiation in cells with the capacity for 
further development remains poorly understood. A recently 
discovered gene, nanog, is required to sustain pluripotency in 
embryonic stem cells and acts concomitantly with embryonic 
transcription factor Oct-4, yet utilizes a STAT-3 independent 
50 mechanism. The subject invention is based on the inventor's 
discovery that gene transfection of adult stem cells with 
nanog, an embryonic stem cell gene maintaining pluripotency 
[8,9], can allow for the production of neurons and astrocytes 
from bone marrow cells via a two-step process. First, mesen-
55 chymal stem cells are modified by nanog transfection, and the 
cells form embryoid-like bodies. Then cells are committed to 
neuronal lineage in a co-culture system with differentiated 
neural stem cells separated by a semi-permeable membrane. 
This technology may be a means of generating effective 
60 autologous stem cell transplants to improve neuroreplace-
ment strategies. The inventors have discovered that adult stem 
cells can be dedifferentiated through introduction and expres-
sion of the nanog gene or other dedifferentiating genes. 
Thus, in one embodiment, the invention provides methods 
65 for making a more developmentally potent cell from a less 
developmentally potent cell. In a typical embodiment, the 
method comprises the step of introducing an expressible 
US 8,906,683 B2 
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dedifferentiating polynucleotide sequence into a less devel-
opmentally potent cell, wherein the transfected less develop-
mentally potent cell becomes a more developmentally potent 
cell capable of differentiating to a less developmentally 
potent cell of its lineage of origin or a different lineage. In 
certain embodiments, the inventive methods further comprise 
the step of co-culturing the transfected less developmentally 
potent with neural-lineage cells or media conditioned with 
neural-lineage cells, wherein the transfected cells become a 
more developmentally potent cells capable of differentiating 
to a less developmentally potent cells of its lineage of origin 
or a different lineage. 
In the practice of one embodiment of the invention, the 
phenotype of the less developmentally potent cell is changed 
when it becomes a more developmentally potent cell. Thus, 
the invention provides methods for changing a first phenotype 
of a less developmentally potent cell into a second phenotype 
of more developmentally potent cell. The change from a 
certain potency to a higher level of potency is considered 
"dedifferentiation" in accord with the teachings herein. In 
preferred embodiments, the less developmentally potent cell 
is a stem cell, more preferably a hematopoietic stem cell, a 
neural stem cell, an epithelial stem cell, an epidermal stem 
cell, a retinal stem cell, an adipose stem cell and a mesenchy-
mal stem cell. 
In yet further aspects of the invention are provided phar-
maceutical compositions comprising said more developmen-
tally potent cells prepared according to the methods of the 
invention and a pharmaceutically-acceptable carrier or 
excipient. The invention provides such pharmaceutical com-
positions comprising said more developmentally potent cells 
that are tissue stem cells for use in cell or tissue regeneration 
or for correcting a disease or disorder in a tissue or animal in 
need thereof. 
Thus, the invention also provides methods for using the 
pharmaceutical compositions provided herein to treat an ani-
mal in need thereof by administering the more developmen-
tally potent cells thereto. In certain preferred embodiments, 
the more developmentally potent cells comprise a cluster of 
two or more of the more developmentally potent cells. Pref-
erably, the animal has a corporal or neurological deficit that 
can be treated or ameliorated by administration of said more 
developmentally potent cells, such as a deficit caused by a 
neurodegenerative disease, a traumatic injury, a neurotoxic 
injury, ischemia, a developmental disorder, a disorder affect-
ing vision, an injury or disease of the spinal cord, a demyeli-
nating disease, an autoimmune disease, an infection, an 
inflammatory disease, or corporal disease, disorder, injury, 
trauma, malfunction, degeneration or loss. In preferred 
embodiments, the one or plurality of more developmentally 
potent cells are capable of migrating to an area of tissue 
damage, differentiating in a tissue-specific manner and func-
tioning in a manner that reduces the neurological or corporal 
deficit. As provided by the methods of the invention herein, 
the cells are administered by injecting one or a plurality of 
more developmentally potent cells with a syringe, inserting 
the more developmentally potent cells with a catheter or 
surgically implanting the more developmentally potent cells. 
4 
the more developmentally potent cells are surgically 
implanted into a body cavity that is fluidly-connected to the 
area of neurological or corporal deficit. In certain preferred 
embodiments, the body cavity is a brain ventricle. The more 
developmentally potent cells can also alternatively be 
inserted using a syringe or catheter or surgically implanted 
directly at the site of the neurological or corporal deficit or 
systemically (e.g., intravenously). 
Also, the more developmentally potent cells may be further 
10 genetically modified through introduction of polynucleotide 
sequences the bias against differentiation to certain cell types 
or bias toward differentiation to certain cell types. Provisional 
Application Nos. 60/621,483 and 60/621,902 naming Dr. 
Kiminobu Sugaya as an inventor and entitled "Methods and 
15 Products For Biasing Development" are incorporated by ref-
erence to provide examples of negative and positive biasing 
that could be subjected to the more developmentally potent 
cells produced by the methods taught herein. 
Administration of the one or a plurality of more develop-
20 mentally potent cells into an animal results in said cells dif-
ferentiating into a terminally-differentiated cell. Thus, the 
invention provides methods for making a terminally-differ-
entiated cell, comprising the step of administering the more 
developmentally potent cells of the invention into an animal 
25 in need thereof. As provided by the methods of the invention 
herein, the cells are administered by injecting the more devel-
opmentally potent cells with a syringe, inserting the more 
developmentally potent cells with a catheter or surgically 
implanting the more developmentally potent cells. In certain 
30 embodiments, the more developmentally potent cells are 
injected with a syringe into a body cavity that is fluidly-
connected to the area of neurological or corporal deficit. In 
certain preferred embodiments, the body cavity is a brain 
ventricle. In other embodiments, the more developmentally 
35 potent cells are inserted with a catheter into a body cavity that 
is fluidly-connected to the area of neurological or corporal 
deficit. In certain preferred embodiments, the body cavity is a 
brain ventricle. In still further additional embodiments, the 
more developmentally potent cells are surgically implanted 
40 into a body cavity that is fluidly-connected to the area of 
neurological or corporal deficit. In certain preferred embodi-
ments, the body cavity is a brain ventricle. The more devel-
opmentally potent cells can also alternatively be inserted 
using a syringe or catheter or surgically implanted directly at 
45 the site of the neurological or corporal deficit or systemically 
(e.g., intravenously). 
In yet another embodiment, the invention relates to treating 
a stem cell, excluding those of neural origin, such that it is 
converted into a more developmentally potent cell, which 
50 enables it to differentiate into the various cell types found in 
eye tissue, inter alia, chorid, Buchs and retinal pigment epi-
thelium cells, rod and cone photoreceptor cells, horizontal 
cells, bipolar neurons, amacrine, ganglion and optic nerve 
cells. These non-limiting, exemplary cell types found in eye 
55 tissue are collectively referred to as retinal cells. The methods 
comprising the step of contacting more developmentally 
potent cells of the invention with an effective amount of one 
or a combination of growth factor selected from the group 
consisting of TGF-b3, IGF-1 and CNTF for an effective In certain embodiments, the more developmentally potent 
cells are injected with a syringe into a body cavity that is 
fluidly-connected to the area of neurological or corporal defi-
cit. In certain preferred embodiments, the body cavity is a 
brain ventricle. In other embodiments, the more developmen-
tally potent cells are inserted with a catheter into a body cavity 
that is fluidly-connected to the area of neurological or corpo- 65 
ral deficit. In certain preferred embodiments, the body cavity 
60 period such that the growth factor-contacted cells can differ-
entiate into retinal cells. 
As used herein, the terms "multipotent neural stem cells 
(MNSCs )," "neural stem cells (NSCs )" and "neural progeni-
tor cells (NPCs)" refer to undifferentiated, multipotent cells 
of the CNS. Such terms are commonly used in the scientific 
literature. MNSCs can differentiate into tissue-specific cell 
types, for example astrocytes, oligodendrocytes, and neurons is a brain ventricle. In still further additional embodiments, 
US 8,906,683 B2 
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when transplanted in the brain. MNSCs of the invention are 
distinguished from natural MNSCs by their adaptation for 
proliferation, migration and differentiation in mammalian 
host tissue when introduced thereto. 
As used herein, a "less developmentally potent cell" is a 
cell that is capable oflimited multi-lineage differentiation or 
capable of single-lineage, tissue-specific differentiation, for 
example, an untreated mesenchymal stem cell can differen-
tiate into, inter alia, osteocytes and chrondrocytes, i.e., cells 
of mesenchymal lineage, but has only limited ability to dif-
ferentiate into cells of other lineages (e.g., neural lineage.). 
As used herein, a "more developmentally potent cell" is a 
cell that is readily capable of differentiating into a greater 
variety of cell types than its corresponding less developmen-
tally potent cell. For example, a mesenchymal stem cell can 
readily differentiate into osteocytes and chrondrocytes but 
has only limited ability to differentiate into neural or retinal 
lineage cells (i.e., it is a less developmentally potent cell in 
this context). Mesenchymal stem cells treated according to 
the methods of the invention become more developmentally 
potent because they can readily differentiate into, for 
example, mesenchymal-lineage and neural-lineage cell 
types; the plasticity of the cells is increased when treated 
according to the methods of the invention. 
6 
the progeny of the more developmentally potent cells can be 
generated from dissociated or isolated tissue and proliferated 
in vitro using the methods described herein. In the case of 
mesenchymal stem cells (MeSCs ), progeny can be generated 
from MeSCs isolated from, for example, bone marrow. Upon 
suitable expansion of cell numbers, the stem cells of the 
invention can be harvested and readied for administration into 
the recipient's affected tissue. 
There are significant differences in the method of delivery 
10 to the brain of the more developmentally potent cells com-
pared to the prior art. One exemplary difference is as follows: 
the more developmentally potent cells of the invention are 
transplanted intraventricularly. Further, while the transplan-
tation of one or more separate more developmentally potent 
15 cells is efficacious, the more developmentally potent cells of 
the invention are preferably transplanted in the form of clus-
ters of two or more cells via a surgical procedure or injection 
using a syringe large enough to leave the clusters substan-
tially intact. The results disclosed in the Examples below 
20 indicate that ventricular delivery of more developmentally 
potent cells of the invention in the form of a cluster of two or 
more cells can result in migration to the area of damage in the 
brain and proper neuronal differentiation. Another benefit of 
intraventricular injection is less tissue destruction, resulting 
25 in less localized recruitment of immune cells by the host. This 
is evidenced by the lack of ventricular distortion, tumor for-
mation, and increased host astrocyte staining without any 
immunosuppression. 
The invention provides methods of delivery and transplan-
tation of the more developmentally potent cells of the inven-
tion to ameliorate the effects of age, physical and biological 
trauma and degenerative disease on the brain or central ner-
vous system of an animal, as well as other tissues such as, for 
example, retinal tissue. It is well recognized in the art that 30 
transplantation of tissue into the CNS offers the potential for 
treatment of neurodegenerative disorders and CNS damage 
due to injury. Transplantation of new cells into the damaged 
CNS has the potential to repair damaged circuitries and pro-
vide neurotransmitters thereby restoring neurological func- 35 
tion. It is also recognized in the art that transplantation into 
other tissue, such as eye tissue, offers the potential for treat-
ment of degenerative disorders and tissue damage due to 
injury. As disclosed herein, the invention provides methods 
for generating more developmentally potent cells adapted for 40 
proliferation, migration and differentiation in mammalian 
tissue when introduced thereto. The use of more developmen-
tally potent cells in the treatment of neurological disorders 
and CNS damage, as well as the use of more developmentally 
potent cells in the treatment of other tissue damage or degen- 45 
eration, can be demonstrated by the use of established animal 
models known in the art. 
The method of delivery of the more developmentally 
potent cells of the invention to the brain can be essentially 
duplicated for other immunoprivileged tissue such as, for 
example, the eye. Delivery of one or more separate or two or 
more of the more developmentally potent cells in the form of 
a cluster via injection using a syringe large enough to leave 
the any cluster of two or more cells that is present substan-
tially intact can result in migration to the area of damage in the 
eye and proper tissue-specific differentiation. 
In the context of the present application, a polynucleotide 
sequence is "homologous" with the sequence according to the 
invention if at least 70%, preferably at least 80%, most pref-
erably at least 90% of its base composition and base sequence 
corresponds to the sequence according to the invention. 
According to the invention, a "homologous protein" is to be 
understood to comprise proteins which contain an amino acid 
sequence at least 70% of which, preferably at least 80% of 
which, most preferably at least 90% of which, corresponds to 
the amino acid sequence shown in FIG. 9; wherein corre-
sponds is to be understood to mean that the corresponding 
amino acids are either identical or are mutually homologous 
In one embodiment dedifferentiated cells or more devel-
opmentally potent cells of the invention can be administered 
to an animal with abnormal or degenerative symptoms 
obtained in any manner, including those obtained as a result 
of age, physical or biological trauma, or neurodegenerative 
disease and the like, or animal models created by man using 
recombinant genetic techniques, such as transgenic and 
"gene knockout" animals. 
Recipients of the more developmentally potent cells of the 
invention can be immunosuppressed, either through the use of 
immunosuppressive drugs such as cyclosporin, or through 
local immunosuppression strategies employing locally 
applied immunosuppressants, but such immunosuppression 
need not necessarily be a prerequisite in certain immunoprivi-
leged tissues such as, for example, brain and eye tissues. In 
certain embodiments, the delivery method of the invention 
can cause less localized tissue damage to the site of cell 
damage or malfunction than existing methods of delivery. 
More developmentally potent cells of the invention can be 
prepared from the recipient's own tissue. In such instances, 
50 amino acids. The expression "homologous amino acids" 
denotes those which have corresponding properties, particu-
larly with regard to their charge, hydrophobic character, steric 
properties, etc. Thus, in one embodiment the protein may be 
55 
from 70% up to less than 100% homologous to nanog. 
Homology, sequence similarity or sequence identity of 
nucleotide or amino acid sequences may be determined con-
ventionally by using known software or computer programs 
such as the BestFit or Gap pairwise comparison programs 
(GCG Wisconsin Package, Genetics Computer Group, 575 
60 Science Drive, Madison, Wis. 53711). BestFit uses the local 
homology algorithm of Smith and Waterman, Advances in 
Applied Mathematics 2: 482-489 (1981), to find the best 
segment of identity or similarity between two sequences. Gap 
performs global alignments: all of one sequence with all of 
65 another similar sequence using the method ofNeedleman and 
Wunsch, J. Mo!. Biol. 48:443-453 (1970). When using a 
sequence alignment program such as BestFit, to determine 
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the degree of sequence homology, similarity or identity, the 
default setting may be used, or an appropriate scoring matrix 
may be selected to optimize identity, similarity or homology 
scores. Similarly, when using a program such as BestFit to 
determine sequence identity, similarity or homology between 
two different amino acid sequences, the default settings may 
be used, or an appropriate scoring matrix, such as blosum45 
or blosum80, may be selected to optimize identity, similarity 
or homology scores. 
The term "isolated" means separated from its natural envi-
ronment. 
The term "polynucleotide" refers in general to polyribo-
nucleotides and polydeoxyribonucleotides, and can denote an 
unmodified RNA or DNA or a modified RNA or DNA. 
The term "polypeptides" is to be understood to mean pep-
tides or proteins which contain two or more amino acids 
which are bound via peptide bonds. 
The polypeptides for use in accord with the teachings 
herein include polypeptides corresponding to nanog, and also 
includes those, at least 70% of which, preferably at least 80% 
of which, are homologous with the polypeptide correspond-
ing to nanog, and most preferably those which exhibit a 
homology of least 90% to 95% with the polypeptide corre-
sponding to nanog and which have dedifferentiating influ-
ence. See polypeptide sequence provided in FIG. 9. Thus, the 
polypeptides may have a homology of from 70% to up to 
100% with respect to nanog. 
As used herein, a "polypeptide sequence exhibiting dedif-
ferentiating influence" is a polypeptide whose presence in the 
cell causes an increase in potency, or transformation from a 
less developmentally potent cell to a more developmentally 
potent cell. Examples of such polypeptide sequences include 
the expression products of the nanog gene, and polynucle-
otide sequences that hybridize to the complement of the 
sequence in FIG. 9, as well as expression products of the 
polynucleotide sequences listed in Table 1 below in Example 
3. 
The terms "stringent conditions" or "stringent hybridiza-
tion conditions" includes reference to conditions under which 
a polynucleotide will hybridize to its target sequence, to a 
detectably greater degree than other sequences (e.g., at least 
2-fold over background). Stringent conditions are sequence-
dependent and will be different in different circumstances. By 
controlling the stringency of the hybridization and/or wash-
ing conditions, target sequences can be identified which are 
100% complementary to the probe (homologous probing). 
Alternatively, stringency conditions can be adjusted to allow 
some mismatching in sequences so that lower degrees of 
similarity are detected (heterologous probing). 
Typically, stringent conditions will be those in which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 MNa ion concentration ( orother salts) at pH 
7 .0 to 8.3 and the temperature is at least about 30° C. for short 
probes (e.g., !Oto 50 nucleotides) and at least about 60° C. for 
long probes (e.g., greater than 50 nucleotides). Stringent con-
ditions may also be achieved with the addition of destabiliz-
ing agents such as formamide. Exemplary low stringency 
conditions include hybridization with a buffer solution of30 
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl 
sulphate) at 37° C., anda wash in lx to 2xSSC (20xSSC=3.0 
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary 
moderate stringency conditions include hybridization in 40 to 
45%formamide, 1MNaCl,1%SDSat37°C.,andawashin 
0.5x to lxSSC at 55 to 60° C. Exemplary high stringency 
conditions include hybridization in 50% formamide, 1 M 
NaCl, 1 % SDS at 37° C., and a washinO.lxSSC at 60 to 65° 
C. 
8 
Specificity is typically the function of post-hybridization 
washes, the critical factors being the ionic strength and tem-
perature of the final wash solution. For DNA-DNA hybrids, 
the Tm can be approximated from the equation ofMeinkoth 
and Wahl, Anal. Biochem., 138:267-284 (1984): 
Tm=81.5oC.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-
500/L; where Mis the molarity of monovalent cations, % GC 
is the percentage of guano sine and cytosine nucleotides in the 
DNA,% form is the percentage offormamide in the hybrid-
10 ization solution, and Lis the length of the hybrid in base pairs. 
The Tm is the temperature (under defined ionic strength and 
pH) at which 50% of a complementary target sequence 
hybridizes to a perfectly matched probe. Tm is reduced by 
about 1 ° C. for each 1 % of mismatching; thus, Tm, hybrid-
15 ization and/or wash conditions can be adjusted to hybridize to 
sequences of the desired identity. For example, if sequences 
with approximately 90% identity are sought, the Tm can be 
decreased 10° C. Generally, stringent conditions are selected 
to be about 5° C. lower than the thermal melting point (Tm) 
20 for the specific sequence and its complement at a defined 
ionic strength and pH. However, severely stringent conditions 
can utilize a hybridization and/or wash at 1, 2, 3, or 4° C. 
lower than the thermal melting point (Tm); moderately strin-
gent conditions can utilize a hybridization and/or wash at 6, 7, 
25 8, 9, or 10° C. lowerthan the thermal melting point (Tm); low 
stringency conditions can utilize a hybridization and/or wash 
at 11, 12, 13, 14, 15, or 20° C. lower than the thermal melting 
point (Tm). Using the equation, hybridization and wash com-
positions, and desired Tm, those of ordinary skill will under-
30 stand that variations in the stringency of hybridization and/or 
wash solutions are inherently described. If the desired degree 
of mismatching results in a Tm ofless than 45° C. (aqueous 
solution) or 32° C. (formamide solution) it is preferred to 
increase the SSC concentration so that a higher temperature 
35 can be used. An extensive guide to the hybridization of 
nucleic acids is found in Current Protocols in Molecular 
Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing 
and Wiley-Interscience, New York (2000). 
Accordingly, polynucleotide sequences that hybridize to 
40 the complement of the sequence in FIG. 9 are contemplated 
for use in dedifferentiating cells as taught herein. 
US. Patent Application Nos. 2003/0219898, 2003/ 
0148513, and 2003/0139410 are incorporated by reference to 
the extent they are not inconsistent with the teachings herein. 
45 These first two of these patent applications describe multiple 
uses of increased potency cells obtained from the taught 
methods, and in particular, the implantation of stem cells for 
different therapeutic treatments of neurological trauma and 
degenerative conditions. The third patent application is 
50 directed to the use of certain compounds to stimulate prolif-
eration and migration of stem cells. Those skilled in the art 
will readily appreciate that the dedifferentiated cells of the 
subject invention could be substituted in place of the potent 
cells taught in the aforementioned patent applications, with-
55 out undue experimentation. Also, the methods of the third 
patent may be combined with the present invention without 
undue experimentation. 
According to another embodiment, the subject invention 
comprises a method of influencing transcription of an endog-
60 enous polynucleotide sequence comprising contacting a non-
embryonic cell or cellular component comprising an endog-
enous polynucleotide sequence with a nanog protein or 
protein encoded by a polynucleotide sequence that hybridizes 
to a complement of the sequence shown in FIG. 9 under 
65 stringent conditions (i.e. nanog-like protein). Such influence 
may further include, but is not limited to, demethylation of 
DNA and reversal histone acetylation. The nanog protein or 
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nanog-like protein may be one expressed by a polynucleotide 
sequence introduced in the cell or cellular component, or 
protein delivered into the cell or cellular component, or pro-
tein expressed by an endogenous polynucleotide sequence 
that has been activated. Nanog expression may be activated 
by the provision of Oct 4 and/or Sox2, which typically form 
a dimer. In a specific embodiment, the cellular component is 
a nucleus, liposome, or mitochondria. Such endogenous 
polynucleotide sequence or cellular component contacted by 
nanog or nanog may be removed from a cell or cellular 10 
component and introduced into another cell or cellular com-
ponent. 
In another specific embodiment, the invention pertains to 
increasing the efficacy of nuclear transfer comprising trans-
fecting a nucleus with a polynucleotide encoding nanog or 15 
nanog-like protein to obtain a treated nucleus and introducing 
the treated nucleus into a cell. The cell may be any suitable 
cell but would typically be an ovum with its nucleus removed. 
10 
studies have shown evidence that adult stem cells can migrate 
and differentiate into various tissues, albeit at extremely low 
frequencies [20]. However, challenges have been raised over 
the plasticity of these cells given both the low frequencies of 
detected cells and new found evidence of cell fusion, in con-
junction with false positives [25-27]. An ideal therapeutic 
alternative may exist if adult cells can be dedifferentiated to 
an embryonic-like state and recommitted to differentiate to a 
desired cell fate. 
Nanog, also referred to as early embryo specific NK (ENK) 
[28], is a recently discovered gene responsible for maintain-
ing pluripotency in embryonic stem cells [8, 9, 28, 29]. This 
unique gene and its cousin, Nanog2, are genetically distinct 
members of the ANTP class of homeodomain proteins [30] 
and have at least twelve identified pseudogenes [31]. Struc-
turally, Nanog contains three alpha helixes encoded within 
the homeodomain portion and can be divided into three 
regions with respect to the central homeodomain sequence 
[30]. The N-terminal region is rich in serine and threonine 
Example 1 
Dedifferentiation ofMesenchymal Stem Cells 
Introduction 
20 residues indicating phosphate-regulated transactivation, pos-
sibly through SMAD4 interactions, while the C-terminal 
domain is seven times as active with an unusual motif of 
equally spaced tryptophans separated by four amino acids, 
each flanked with serine or threonine residues. Gene expres-
25 sion studies have shown nanog to be active in embryonic stem 
cells, tumors and some adult tissue. Nanog expression pre-
cipitously decreases with differentiation and maintains self-
renewal in embryonic stem cells by gene transfection. In 
culture, nanog guards against differentiation and acts con-
Embryonic stem cells are derived during the blastocyst 
stage from the inner cell mass of prenatal mammalia; and 
possess the intrinsic properties of rapid self-renewal and 
pluripotency. Under the influence of endogenous and extra-
cellular signals, these cells migrate and differentiate during 
the developmental process. Extracellular signals regulating 
self-renewal or differentiation have been demonstrated in 
vitro by differentiating embryonic stem cells into cell types 
comprising all three germ layers. These varieties include 
neuronal, pancreatic, cardiac and hematopoietic tissue using 
well-established culturing protocols. Embryonic stem cells 35 
form embryoid bodies, non-adherent proliferating clusters, in 
the presence ofleukemia-inhibitory factor (LIF) and a feeder 
layer of typically fibroblast cells. Upon removal of LIF or 
transfer to non-feeder cell cultures, embryoid bodies undergo 
spontaneous differentiation. Early differentiation is charac-
terized by loss of stem cell-specific surface antigens (SSEA-
1) and alkaline phosphatase activity. Additionally, endog-
enous signals, including regulatory intracellular proteins, 
continually change throughout development. Numerous gene 
expression studies show distinct variations among different 
embryonic and adult stem cells, pointing toward underlying 
mechanisms responsible for the continual loss of potency 
corresponding with differentiation. Several key genes, 
namely Oct-3/4, LIF, DNMT3B and Nanog, are repeatedly 
shown to be almost exclusively expressed in embryonic stem 
cells that regulate pluripotency [10-14]. The immediate 
down-regulation of these genes may explain irreversible loss 
of potency, making embryonic stem cells an attractive source 
for clinical therapies. However, serious questions remain con-
cerning the production of these cells in sufficient quantities 
for therapies, bioethical potential immune response and 
tumor formation [15]. 
30 comitantly with Oct-4, Wnt and BMP-4, yet utilizes a STAT-3 
independent mechanism to maintain an undifferentiated 
state. Inventors believe that the role of nanog in regulating 
pluripotency makes this gene a potential candidate for 
increasing the potency of adult stem cells. 
Previous studies regulating gene expression in stem cell 
lines have provided valuable insight into underlying mecha-
nisms of proliferation, self-renewal and differentiation. Gene 
manipulation experiments can either prevent or enhance dif-
ferentiation. In particular, differentiation can be prevented in 
40 embryonic stem cell lines by over expression of Pem or 
nanog, genes that regulate pluripotency. Conversely, over-
expression of lineage specific gene Nurrl promotes the dif-
ferentiation of neura 1 stem cell lines to produce dopamine-
secreting cells. Taken together, gene vectors can maintain 
45 cells in a specific state or allow for lineage committed cells to 
develop into a specific subpopulation. In one embodiment, 
the subject invention pertains to a method of dedifferentiating 
adult stem cells by expressing genes regulating pluripotency 
to enhance transdifferentiation. This technology allows for 
50 adult cells to be used for autologous transplantation and 
thereby provide a greater understanding of stem cell biology. 
FIG. 17 shows a schematic representation of the nanog 
sequence cloned inside a CMV mammalian promoter vector. 
The 5'UTR contains an Oct-4 and Sox2 binding region. The 
55 nanog protein coding sequence can be divided into an N-ter-
minal, homeodomain and C-terminal region. The C-terminal 
region can be further subdivided into a Cl, Cw and C2 
domains. The 3' UTR contains an Alu sequence element. The inventors believe that adult stem cells offer a practi-
cable alternative to the use of embryonic tissue as they are 
easily harvested and potentially taken from autologous 60 
sources to preclude immune response. Stem cell populations 
have been found in several adult tissues including adipose 
[16], muscle [17], pancrease [18] and liver [19] and primarily 
bone marrow [20-23]; all potential sources for cellular trans-
plants [24]. Previous in vitro studies with adult bone marrow- 65 
derived stem cells have demonstrated the ability to differen-
tiate into brain [21], liver [23] and cardiac cells [22]. In vivo 
Methods and Results 
Human mesenchymal stem cells (hMeSC) are initially 
plated in 6-well plates, adhere to the surface and allowed to 
divide to varying degrees of confluence. They are cultured in 
serum-DMEM (Dulbecco's modified Eagle's medium) con-
taining 10% FCS, 5% HS, 292 mg/ml glutamine, 50 U/ml 
streptomycin and penicillin (all from Invitrogen). 
Cloning of nanog was achieved by first performing poly-
merase chain reaction with primers corresponding to the 
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nanog gene family (5'-tttttcctcctcttcctcta-3', SEQ ID NO. 3, 
and 5'-attggtgatgaagatgtatt-3' SEQ ID NO. 4) against a 
human genome DNA template. The PCR product was cloned 
into pcDNA Hismax TOPO TA cloning mammalian expres-
sion vector (Invitrogen) and inserted in E coli. See FIG. 1. 
Bacterial cells were plated on agar plates containing LB agar 
and ampacillin and incubated overnight at 37° C. Isolated 
colonies were transferred to growth media and grown over-
night in a 37° C. rotating at 200 rpm. Plasmid isolation was 
performed using endotoxin free maxiprep (Beckon Dicken-
son) or miniprep kits (Clonetech). Gene segment was then 
confirmed by gel electrophoresis through enzyme digestion 
and DNA sequencing. The gene product was approximately 
1600 base pairs, consistent with the nanog gene. However, 
sequencing analysis matched nanog pseudogene 8 
(NANOG8), a segment containing no intrans and sharing 99 
percent homology with nanog. See. The deduced protein 
product is almost identical with two differing amino acids. 
The gene product encodes for a nanog-like protein with a 305 
amino acid serine/threonine-rich sequence. The protein can 20 
be divided into three distinct domains at the N-terminal, 
homeodomain and C-terminal as previously described. 
formed mesenchymal cells. Neural stem cells spheres were 
placed in 12 well plates and differentiated using serum-free 
basal media as previously described. Neuronal stem cells 
began to differentiate by becoming adherent and migrating 
radially outwards from the original neural sphere. Following 
neural stem cell differentiation, these cells were utilized as 
feeder cells in our co-culture system by placing modified cells 
inside co-culture chamber that separated modified stem cells 
from the feeder layer with a 0.2 µm semipermeable mem-
lO brane. See FIG. 5. Within 48 hours, transferred cells began to 
display characteristics of differentiation marked by morpho-
logical alterations, membrane adherence and outward migra-
tion. FIG. 6. Immunohistochemical analysis revealed positive 
15 markers for ~ -III tubulin and GF AP, showing neuron and glial 
differentiation. Positive staining for mixed neuronal popula-
tions was observed in non-adherent clusters cultured for more 
than 48 hours, adherent cell masses and individual membrane 
bound cells. 
Upon reaching a desired cell number, approximately 75% 
confluence, HMeSCs were transfected with above-men-
tioned vector using NeuroPorter (Gene Therapy System) 25 
transfection system. Concentrations of NeuroPorter and 
DNA (0.5 µg/ml to 40 µg/ml) were varied to achieve optimal 
results. Cells became non-adherent and began to multiply, 
forming spherical clusters: consistent with embryoid body 
formation. Thus, they achieved characteristics of embryonic 30 
stem cells. 
Nanog transfection of mesenchymal stem cells resulted in 
morphological changes similar to embryoid body formation 
(FIG. 2-4). Cellular transformation occurred in a pattern of 
transfection, non-adherence, survival and proliferation. Non- 35 
adherent clusters proliferated in vitro beyond two months in 
the presence of remaining adherent mesenchymal stem cells. 
To determine if nanog could restore pluripotency in adult 
cells rather than simply maintain the state in embryonic cells, 
the inventors developed a two-step process of dedifferentia- 40 
tion and development along an alternative lineage, discussed 
in Example 2 below. Human mesenchymal stem cells were 
cultured in a six-well culture plates and were allowed to 
adhere and grow for at least 48 hours to achieve approxi-
mately 7 5% confluence. Cells were subsequently transfected 45 
with a mammalian cell vector or control vehicle, cultured and 
examined. Cells transfected with NANOGP8 became non-
adherent and proliferated in the presence of the remaining 
adherent cells acting as a feeder layer. Control samples 
receiving empty transfection did not show any proliferation 50 
and decreased dramatically, likely due to the toxicity of the 
transfection. Transferring non-adherent cells to wells without 
a feeder layer resulted in apoptosis, related to either absence 
of feeder cell proteins of decreased cell density. Cellular 
transformation occurred in a pattern of transfection, non- 55 
adherence, survival and proliferation. Transformed cells pro-
liferated in three-dimensional clusters for months in culture. 
These characteristics are similar to embryonic stem cells. 
Example 2 
Neuronal Differentiation of Dedifferentiated 
Mesenchymal Cells 
60 
Co-culturing experiments showed embryoid body-like 
clusters began differentiation within 48 hours. Control cells 
with our vector treatments failed to show any signs of neural 
differentiation. Immunohistochemical staining revealed 
nanog transfected samples intensely stained positive for ~III-
tubulin and GFAP, indicating neuron and astrocyte differen-
tiation. See FIGS. 6-7. Originally, nanog-transformed cells 
remain in a cluster of differentiating neural cells that continu-
ally radiate outward (See FIGS. 6-7). FIG. 8 shows MeSC 
derived neurons and astrocytes. 
Example 3 
Dedifferentiation of Cells Utilizing Genes Affecting 
Pluripotency 
Following the transfection and evaluation protocol pro-
vided above in Example 1, PCR products of the genes in Table 
1 are evaluated for their ability to dedifferentiate cells, par-
ticularly mesenchymal stem cells. 
TABLE 1 
Pem (mouse GI: 1255173) 
Fan Y, et al. Developmental Biology 210: 481-496. 1999 
POU5Fl (Unigene Hs.2860) 
Sox2 (Unigene Hs.816) 
HESXl (Unigene Hs.171980) 
UTFl (Unigene Hs.158307) 
REX! (Unigene Hs.335787) 
FOXD3 (Unigene Hs.120204) 
GBX2 (Unigene Hs.326290) 
NANOG (Unigene Hs.326290) 




Richards M, et al. Stem Cells 22: 51-64. 2004 
EGS-1 (accession# X57708.1) 
FGF4 Tanaka T, et al. Genone Research 12: 1921-1928. 2002. 
Rex-1 (accession #AF450454) 
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Example 4 
Cardiac Differentiation of Human Mesenchymal 
Cells 
Cardiac differentiation of human mesenchymal stem cells 
(MeSCs) is achieved through treatment with nucleotide 
US 8,906,683 B2 
15 
derivatives BrdU and 5-azaC and/or forced expression of 
embryonic stem cell gene nanog. Following treatment, cells 
were placed in a co-culture with cardiac cells ( cardiomyocyte 
cell line H9c2). Human MeSCs plated in 6-well culture plates 
and expanded in serum-DMEM (Delbecco's Modified 
Eagle's Medium) containing 10% MeSC formulated fetal 
bovine serum (FBS, Stem Cell, Inc) containing antibiotics/ 
antimycotics. MeSCs were treated with varying concentra-
tions (1-10 uM) of BrdU and/or 5-azaC for 3 weeks or trans-
fected with mammalian expression vector containing a nanog 
encoding sequence. Cell media was changed every three days 
prior to co-culture with cardiomyocytes. Cardiomyocytes 
were expanded and grown to near confluence in serum-
DMEM with 10% non-conditioned FBS and antibiotics/anti-
mycotics. To differentiate cardiac cells, serum media was 
replaced with plain DMEM containing only antibiotics and 
allowed to differentiate. Co-cultures were created by combin-
ing MeSCs with cardiac cells and culturing in cardiac media. 
Following co-culture, cells were treated with TRizol and gene 
expression was assessed using RT-PCR and cardiac specific 
primers. Gel electrophoresis of samples revealed expression 
of cardiac specific genes following treatment. 
16 
diomyocytes and primers are human specific and represent 
markers of cardiomyocyte related gene expression. The sec-
ond data set (Electrophoresis 050115, FIG. 11) shows gene 
expression for each primer following 3 uM treatment of either 
BrdU or SazaC. The high and low RNA is because we had low 
cell numbers and tested one well (low RNA) against combin-
ing two wells of equal treatment (high RNA). The third 
attachment (Electrophoresis 050116, FIG. 12) shows the 
effects of three weeks treatment of combined (3 uM or 1 uM 
10 of both SazaC and BrdU), 3 uM of either SazaC or BrdU, or 
nanog transfected cells (marked "control"). The poor quality 
is the result of low cell numbers and the use of a different 
RT-PCR kit (BioRad instead of the usual Invitrogen). See also 
FIG. 13. FI GS. 14-16 pertain to photograph images ofMeSCs 
15 treated with 3 uM ofSazaC (A 050123 3 uM SazaC 3 weeks 
MSC.jpg, FIG. 14), of3 uM ofBrdU (A 050123 3 uM BrdU 
3 weeks MSC.jpg, FIG. 15) and of nanog transfected cells 
combined with rat cardiac cells in co-culture (A 41227 of 
ntMSC 1213 2.jpg, FIG. 16). The cell differentiation is due to 
20 environmental signals and cell to cell contacts. 
The inventors demonstrate that treatment with nucleotide 
The first (Electrophoresis 050101, FIG.10) shows screens 
for each primer tested. The key shows which sample is in a 
given lane. Negative control represents untreated mesenchy- 25 
ma! stem cells and Positive controls 1 x and 2x are nanog 
transfected MeSCs (2x indicates that well received twice the 
number of rat cardiac cells, not twice the amount of nanog 
transfected cells). Each sample was co-cultured with rat car-
derivatives and/or nanog transfection provides for cardiac 
differentiation of mesenchymal stem cells. Accordingly, an 
embodiment of the invention pertains to a method of increas-
ing the potency of a cell comprising introducing a gene com-
prising nanog activity, optionally in conjunction with treat-
ment of such cell with a compound, such as a nucleotide 
derivative, known to exert a dedifferentiating influence on 
cells. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 9 
<210> SEQ ID NO 1 
<211> LENGTH, 1628 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (28) .. (945) 
<400> SEQUENCE, 1 
tttttcctcc tcttcctcta tactaac atg agt gtg gat cca get tgt CCC caa 54 
Met Ser Val Asp Pro Ala Cys Pro Gln 
1 5 
age ttg cct tgc ttt gaa gaa tee gac tgt aaa gaa tct tea cct atg 102 
Ser Leu Pro Cys Phe Glu Glu Ser Asp Cys Lys Glu Ser Ser Pro Met 
10 15 20 25 
cct gtg att tgt ggg cct gaa gaa aac tat cca tee ttg caa atg tct 150 
Pro Val Ile Cys Gly Pro Glu Glu Asn Tyr Pro Ser Leu Gln Met Ser 
30 35 40 
tct get gag atg cct cac aca gag act gtc tct cct ctt cct tee tee 198 
Ser Ala Glu Met Pro His Thr Glu Thr Val Ser Pro Leu Pro Ser Ser 
45 50 55 
atg gat ctg ctt att cag gac age cct gat tct tee ace agt CCC aaa 246 
Met Asp Leu Leu Ile Gln Asp Ser Pro Asp Ser Ser Thr Ser Pro Lys 
60 65 70 
ggc aaa caa CCC act tct gca gag aat agt gtc gca aaa aag gaa gac 294 
Gly Lys Gln Pro Thr Ser Ala Glu Asn Ser Val Ala Lys Lys Glu Asp 
75 80 85 
aag gtc ccg gtc aag aaa cag aag ace aga act gtg ttc tct tee ace 342 
Lys Val Pro Val Lys Lys Gln Lys Thr Arg Thr Val Phe Ser Ser Thr 
90 95 100 105 
cag ctg tgt gta etc aat gat aga ttt cag aga cag aaa tac etc age 390 
US 8,906,683 B2 
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-continued 
Gln Leu Cys Val Leu Asn Asp Arg Phe Gln Arg Gln Lys Tyr Leu Ser 
110 115 120 
etc cag cag atg caa gaa etc tee aac ate ctg aac etc age tac aaa 
Leu Gln Gln Met Gln Glu Leu Ser Asn Ile Leu Asn Leu Ser Tyr Lys 
125 130 135 
cag gtg aag ace tgg ttc cag aac cag aga atg aaa tct aag agg tgg 
Gln Val Lys Thr Trp Phe Gln Asn Gln Arg Met Lys Ser Lys Arg Trp 
140 145 150 
cag aaa aac aac tgg ccg aag aat age aat ggt gtg acg cag aag gee 
Gln Lys Asn Asn Trp Pro Lys Asn Ser Asn Gly Val Thr Gln Lys Ala 
155 160 165 
tea gca cct ace tac ccc age etc tac tct tee tac cac cag gga tgc 
Ser Ala Pro Thr Tyr Pro Ser Leu Tyr Ser Ser Tyr His Gln Gly Cys 
170 175 180 185 
ctg gtg aac ccg act ggg aac ctt cca atg tgg age aac cag ace tgg 
Leu Val Asn Pro Thr Gly Asn Leu Pro Met Trp Ser Asn Gln Thr Trp 
190 195 200 
aac aat tea ace tgg age aac cag ace cag aac ate cag tee tgg age 
Asn Asn Ser Thr Trp Ser Asn Gln Thr Gln Asn Ile Gln Ser Trp Ser 
205 210 215 
aac cac tee tgg aac act cag ace tgg tgc ace caa tee tgg aac aat 
Asn His Ser Trp Asn Thr Gln Thr Trp Cys Thr Gln Ser Trp Asn Asn 
220 225 230 
cag gee tgg aac agt ccc ttc tat aac tgt gga gag gaa tct ctg cag 
Gln Ala Trp Asn Ser Pro Phe Tyr Asn Cys Gly Glu Glu Ser Leu Gln 
235 240 245 
tee tgc atg cac ttc cag cca aat tct cct gee agt gac ttg gag get 
Ser Cys Met His Phe Gln Pro Asn Ser Pro Ala Ser Asp Leu Glu Ala 
250 255 260 265 
gee ttg gaa get get ggg gaa ggc ctt aat gta ata cag cag ace act 
Ala Leu Glu Ala Ala Gly Glu Gly Leu Asn Val Ile Gln Gln Thr Thr 
270 275 280 
agg tat ttt agt act cca caa ace atg gat tta ttc eta aac tac tee 
Arg Tyr Phe Ser Thr Pro Gln Thr Met Asp Leu Phe Leu Asn Tyr Ser 
285 290 295 
atg aac atg caa cct gaa gac gtg tga agatgagtga aactgatatt 
Met Asn Met Gln Pro Glu Asp Val 
300 305 
actcaatttc agtctggaca ctggctgaat ccttcctctc ccctcctccc atccctcata 
ggatttttct tgtttggaaa ccacgtgttc tggtttccat gatgcctatc cagtcaatct 
catggagggt ggagtatggt tggagcctaa tcagcgaggt ttcttttttt ttttttccta 
ttggatcttc ctggagaaaa tacttttttt tttttttttg agacggagtc ttgctctgtc 
gcccaggctg gagtgcagtg gcgcggtctt ggctcactgc aagctccgcc tcccgggttc 
acgccattct cctgcctcag cctcccgagc agctgggact acaggcgccc gccacctcgc 
ccggctaata ttttgtattt ttagtagaga cagggtttca ctgtgttagc caggatggtc 
tcgatctcct gaccttgtga tccgcccgcc tcggcctccc taacagctgg gattacaggc 
gtgagccacc gcgccctgcc tagaaaagac attttaataa ccttggctgc taaggacaac 
attgatagaa gccgtctctg gctatagata agtagatcta atactagttt ggatatcttt 
agggtttaga atctaacctc aagaataaga aatacaagta cgaattggtg atgaagatgt 
att 
<210> SEQ ID NO 2 
<211> LENGTH, 305 
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-continued 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
Met Ser Val Asp Pro Ala Cys Pro Gln Ser Leu Pro Cys Phe Glu Glu 
1 5 10 15 
Ser Asp Cys Lys Glu Ser Ser Pro Met Pro Val Ile Cys Gly Pro Glu 
20 25 30 
Glu Asn Tyr Pro Ser Leu Gln Met Ser Ser Ala Glu Met Pro His Thr 
35 40 45 
Glu Thr Val Ser Pro Leu Pro Ser Ser Met Asp Leu Leu Ile Gln Asp 
50 55 60 
Ser Pro Asp Ser Ser Thr Ser Pro Lys Gly Lys Gln Pro Thr Ser Ala 
65 70 75 80 
Glu Asn Ser Val Ala Lys Lys Glu Asp Lys Val Pro Val Lys Lys Gln 
85 90 95 
Lys Thr Arg Thr Val Phe Ser Ser Thr Gln Leu Cys Val Leu Asn Asp 
100 105 110 
Arg Phe Gln Arg Gln Lys Tyr Leu Ser Leu Gln Gln Met Gln Glu Leu 
115 120 125 
Ser Asn Ile Leu Asn Leu Ser Tyr Lys Gln Val Lys Thr Trp Phe Gln 
130 135 140 
Asn Gln Arg Met Lys Ser Lys Arg Trp Gln Lys Asn Asn Trp Pro Lys 
145 150 155 160 
Asn Ser Asn Gly Val Thr Gln Lys Ala Ser Ala Pro Thr Tyr Pro Ser 
165 170 175 
Leu Tyr Ser Ser Tyr His Gln Gly Cys Leu Val Asn Pro Thr Gly Asn 
180 185 190 
Leu Pro Met Trp Ser Asn Gln Thr Trp Asn Asn Ser Thr Trp Ser Asn 
195 200 205 
Gln Thr Gln Asn Ile Gln Ser Trp Ser Asn His Ser Trp Asn Thr Gln 
210 215 220 
Thr Trp Cys Thr Gln Ser Trp Asn Asn Gln Ala Trp Asn Ser Pro Phe 
225 230 235 240 
Tyr Asn Cys Gly Glu Glu Ser Leu Gln Ser Cys Met His Phe Gln Pro 
245 250 255 
Asn Ser Pro Ala Ser Asp Leu Glu Ala Ala Leu Glu Ala Ala Gly Glu 
260 265 270 
Gly Leu Asn Val Ile Gln Gln Thr Thr Arg Tyr Phe Ser Thr Pro Gln 
275 280 285 
Thr Met Asp Leu Phe Leu Asn Tyr Ser Met Asn Met Gln Pro Glu Asp 
Val 
305 
290 295 300 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 3 
tttttcctcc tcttcctcta 
<210> SEQ ID NO 4 
20 
20 
<211> LENGTH, 20 
<212> TYPE, DNA 
21 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 4 
attggtgatg aagatgtatt 
<210> SEQ ID NO 5 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
20 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
6 His Tag 
<400> SEQUENCE, 5 
His His His His His His 
1 
<210> SEQ ID NO 6 
<211> LENGTH, 1417 
<212> TYPE, DNA 
5 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 4 
tcccttcgca agccctcatt tcaccaggcc cccggcttgg ggcgccttcc ttccccatgg 
cgggacacct ggcttcggat ttcgccttct cgccccctcc aggtggtgga ggtgatgggc 
caggggggcc ggagccgggc tgggttgatc ctcggacctg gctaagcttc caaggccctc 
ctggagggcc aggaatcggg ccgggggttg ggccaggctc tgaggtgtgg gggattcccc 
catgcccccc gccgtatgag ttctgtgggg ggatggcgta ctgtgggccc caggttggag 
tggggctagt gccccaaggc ggcttggaga cctctcagcc tgagggcgaa gcaggagtcg 
gggtggagag caactccgat ggggcctccc cggagccctg caccgtcacc cctggtgccg 
tgaagctgga gaaggagaag ctggagcaaa acccggagga gtcccaggac atcaaagctc 
tgcagaaaga actcgagcaa tttgccaagc tcctgaagca gaagaggatc accctgggat 
atacacaggc cgatgtgggg ctcaccctgg gggttctatt tgggaaggta ttcagccaaa 
cgaccatctg ccgctttgag gctctgcagc ttagcttcaa gaacatgtgt aagctgcggc 
ccttgctgca gaagtgggtg gaggaagctg acaacaatga aaatcttcag gagatatgca 
aagcagaaac cctcgtgcag gcccgaaaga gaaagcgaac cagtatcgag aaccgagtga 
gaggcaacct ggagaatttg ttcctgcagt gcccgaaacc cacactgcag cagatcagcc 
acatcgccca gcagcttggg ctcgagaagg atgtggtccg agtgtggttc tgtaaccggc 
gccagaaggg caagcgatca agcagcgact atgcacaacg agaggatttt gaggctgctg 
ggtctccttt ctcaggggga ccagtgtcct ttcctctggc cccagggccc cattttggta 
ccccaggcta tgggagccct cacttcactg cactgtactc ctcggtccct ttccctgagg 
gggaagcctt tccccctgtc tccgtcacca ctctgggctc tcccatgcat tcaaactgag 
gtgcctgccc ttctaggaat gggggacagg gggaggggag gagctaggga aagaaaacct 
ggagtttgtg ccagggtttt tgggattaag ttcttcattc actaaggaag gaattgggaa 
cacaaagggt gggggcaggg gagtttgggg caactggttg gagggaaggt gaagttcaat 
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gacacagtaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 
<210> SEQ ID NO 7 
<211> LENGTH, 360 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
-continued 
Met Ala Gly His Leu Ala Ser Asp Phe Ala Phe Ser Pro Pro Pro Gly 
1 5 10 15 
Gly Gly Gly Asp Gly Pro Gly Gly Pro Glu Pro Gly Trp Val Asp Pro 
20 25 30 
Arg Thr Trp Leu Ser Phe Gln Gly Pro Pro Gly Gly Pro Gly Ile Gly 
35 40 45 
Pro Gly Val Gly Pro Gly Ser Glu Val Trp Gly Ile Pro Pro Cys Pro 
50 55 60 
Pro Pro Tyr Glu Phe Cys Gly Gly Met Ala Tyr Cys Gly Pro Gln Val 
65 70 75 80 
Gly Val Gly Leu Val Pro Gln Gly Gly Leu Glu Thr Ser Gln Pro Glu 
85 90 95 
Gly Glu Ala Gly Val Gly Val Glu Ser Asn Ser Asp Gly Ala Ser Pro 
100 105 110 
Glu Pro Cys Thr Val Thr Pro Gly Ala Val Lys Leu Glu Lys Glu Lys 
115 120 125 
Leu Glu Gln Asn Pro Glu Glu Ser Gln Asp Ile Lys Ala Leu Gln Lys 
130 135 140 
Glu Leu Glu Gln Phe Ala Lys Leu Leu Lys Gln Lys Arg Ile Thr Leu 
145 150 155 160 
Gly Tyr Thr Gln Ala Asp Val Gly Leu Thr Leu Gly Val Leu Phe Gly 
165 170 175 
Lys Val Phe Ser Gln Thr Thr Ile Cys Arg Phe Glu Ala Leu Gln Leu 
180 185 190 
Ser Phe Lys Asn Met Cys Lys Leu Arg Pro Leu Leu Gln Lys Trp Val 
195 200 205 
Glu Glu Ala Asp Asn Asn Glu Asn Leu Gln Glu Ile Cys Lys Ala Glu 
210 215 220 
Thr Leu Val Gln Ala Arg Lys Arg Lys Arg Thr Ser Ile Glu Asn Arg 
225 230 235 240 
Val Arg Gly Asn Leu Glu Asn Leu Phe Leu Gln Cys Pro Lys Pro Thr 
245 250 255 
Leu Gln Gln Ile Ser His Ile Ala Gln Gln Leu Gly Leu Glu Lys Asp 
260 265 270 
Val Val Arg Val Trp Phe Cys Asn Arg Arg Gln Lys Gly Lys Arg Ser 
275 280 285 
Ser Ser Asp Tyr Ala Gln Arg Glu Asp Phe Glu Ala Ala Gly Ser Pro 
290 295 300 
Phe Ser Gly Gly Pro Val Ser Phe Pro Leu Ala Pro Gly Pro His Phe 
305 310 315 320 
Gly Thr Pro Gly Tyr Gly Ser Pro His Phe Thr Ala Leu Tyr Ser Ser 
325 330 335 
Val Pro Phe Pro Glu Gly Glu Ala Phe Pro Pro Val Ser Val Thr Thr 
340 345 350 




<210> SEQ ID NO 8 
<211> LENGTH, 2518 
<212> TYPE, DNA 
25 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
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ctattaactt gttcaaaaaa gtatcaggag ttgtcaaggc agagaagaga gtgtttgcaa 
aagggggaaa gtagtttgct gcctctttaa gactaggact gagagaaaga agaggagaga 
gaaagaaagg gagagaagtt tgagccccag gcttaagcct ttccaaaaaa taataataac 
aatcatcggc ggcggcagga tcggccagag gaggagggaa gcgctttttt tgatcctgat 
tccagtttgc ctctctcttt ttttccccca aattattctt cgcctgattt tcctcgcgga 
gccctgcgct cccgacaccc ccgcccgcct cccctcctcc tctccccccg cccgcgggcc 
ccccaaagtc ccggccgggc cgagggtcgg cggccgccgg cgggccgggc ccgcgcacag 
cgcccgcatg tacaacatga tggagacgga gctgaagccg ccgggcccgc agcaaacttc 
ggggggcggc ggcggcaact ccaccgcggc ggcggccggc ggcaaccaga aaaacagccc 
ggaccgcgtc aagcggccca tgaatgcctt catggtgtgg tcccgcgggc agcggcgcaa 
gatggcccag gagaacccca agatgcacaa ctcggagatc agcaagcgcc tgggcgccga 
gtggaaactt ttgtcggaga cggagaagcg gccgttcatc gacgaggcta agcggctgcg 
agcgctgcac atgaaggagc acccggatta taaataccgg ccccggcgga aaaccaagac 
gctcatgaag aaggataagt acacgctgcc cggcgggctg ctggcccccg gcggcaatag 
catggcgagc ggggtcgggg tgggcgccgg cctgggcgcg ggcgtgaacc agcgcatgga 
cagttacgcg cacatgaacg gctggagcaa cggcagctac agcatgatgc aggaccagct 
gggctacccg cagcacccgg gcctcaatgc gcacggcgca gcgcagatgc agcccatgca 
ccgctacgac gtgagcgccc tgcagtacaa ctccatgacc agctcgcaga cctacatgaa 
cggctcgccc acctacagca tgtcctactc gcagcagggc acccctggca tggctcttgg 
ctccatgggt tcggtggtca agtccgaggc cagctccagc ccccctgtgg ttacctcttc 
ctcccactcc agggcgccct gccaggccgg ggacctccgg gacatgatca gcatgtatct 
ccccggcgcc gaggtgccgg aacccgccgc ccccagcaga cttcacatgt cccagcacta 
ccagagcggc ccggtgcccg gcacggccat taacggcaca ctgcccctct cacacatgtg 
agggccggac agcgaactgg aggggggaga aattttcaaa gaaaaacgag ggaaatggga 
ggggtgcaaa agaggagagt aagaaacagc atggagaaaa cccggtacgc tcaaaaagaa 
aaaggaaaaa aaaaaatccc atcacccaca gcaaatgaca gctgcaaaag agaacaccaa 
tcccatccac actcacgcaa aaaccgcgat gccgacaaga aaacttttat gagagagatc 
ctggacttct ttttggggga ctatttttgt acagagaaaa cctggggagg gtggggaggg 
cgggggaatg gaccttgtat agatctggag gaaagaaagc tacgaaaaac tttttaaaag 
ttctagtggt acggtaggag ctttgcagga agtttgcaaa agtctttacc aataatattt 
agagctagtc tccaagcgac gaaaaaaatg ttttaatatt tgcaagcaac ttttgtacag 
tatttatcga gataaacatg gcaatcaaaa tgtccattgt ttataagctg agaatttgcc 
aatatttttc aaggagaggc ttcttgctga attttgattc tgcagctgaa atttaggaca 
gttgcaaacg tgaaaagaag aaaattattc aaatttggac attttaattg tttaaaaatt 
gtacaaaagg aaaaaattag aataagtact ggcgaaccat ctctgtggtc ttgtttaaaa 
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atgcaggttg acaccgttgg taatttataa tagcttttgt tcgatcccaa ctttccattt 
tgttcagata aaaaaaacca tgaaattact gtgtttgaaa tattttctta tggtttgtaa 
tatttctgta aatttattgt gatattttaa ggttttcccc cctttatttt ccgtagttgt 
attttaaaag attcggctct gtattatttg aatcagtctg ccgagaatcc atgtatatat 
ttgaactaat atcatcctta taacaggtac attttcaact taagttttta ctccattatg 
cacagtttga gataaataaa tttttgaaat atggacactg aaaaaaaaaa aaaaaaaa 
<210> SEQ ID NO 9 
<211> LENGTH, 317 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 9 
Met Tyr Asn Met Met Glu Thr Glu Leu Lys Pro Pro Gly Pro Gln Gln 
1 5 10 15 
Thr Ser Gly Gly Gly Gly Gly Asn Ser Thr Ala Ala Ala Ala Gly Gly 
20 25 30 
Asn Gln Lys Asn Ser Pro Asp Arg Val Lys Arg Pro Met Asn Ala Phe 
35 40 45 
Met Val Trp Ser Arg Gly Gln Arg Arg Lys Met Ala Gln Glu Asn Pro 
50 55 60 
Lys Met His Asn Ser Glu Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys 
65 70 75 80 
Leu Leu Ser Glu Thr Glu Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg 
85 90 95 
Leu Arg Ala Leu His Met Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro 
100 105 110 
Arg Arg Lys Thr Lys Thr Leu Met Lys Lys Asp Lys Tyr Thr Leu Pro 
115 120 125 
Gly Gly Leu Leu Ala Pro Gly Gly Asn Ser Met Ala Ser Gly Val Gly 
130 135 140 
Val Gly Ala Gly Leu Gly Ala Gly Val Asn Gln Arg Met Asp Ser Tyr 
145 150 155 160 
Ala His Met Asn Gly Trp Ser Asn Gly Ser Tyr Ser Met Met Gln Asp 
165 170 175 
Gln Leu Gly Tyr Pro Gln His Pro Gly Leu Asn Ala His Gly Ala Ala 
180 185 190 
Gln Met Gln Pro Met His Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn 
195 200 205 
Ser Met Thr Ser Ser Gln Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser 
210 215 220 
Met Ser Tyr Ser Gln Gln Gly Thr Pro Gly Met Ala Leu Gly Ser Met 
225 230 235 240 
Gly Ser Val Val Lys Ser Glu Ala Ser Ser Ser Pro Pro Val Val Thr 
245 250 255 
Ser Ser Ser His Ser Arg Ala Pro Cys Gln Ala Gly Asp Leu Arg Asp 
260 265 270 
Met Ile Ser Met Tyr Leu Pro Gly Ala Glu Val Pro Glu Pro Ala Ala 
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-continued 
Pro Ser Arg Leu His Met Ser Gln His Tyr Gln Ser Gly Pro Val Pro 
290 295 300 
Gly Thr Ala Ile Asn Gly Thr Leu Pro Leu Ser His Met 
305 310 315 
What is claimed is: 10 
1. A method of transforming an adult mesenchymal stem 
cell into a pluripotent cell, said method comprising introduc-
ing into said adult mesenchymal stem cell an oct4 gene and a 
sox 2 gene and culturing said adult mesenchymal stem cell 
under conditions to produce expression of said oct4 and sox 2 15 
genes, wherein said expression results in said adult mesen-
chymal stem cell becoming a pluripotent cell. 
* * * * * 
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